Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
From persons involved with getting the positing filled.
New person should be starting this coming week. Internal fill of position who has long history with Vivos and good tech background. Be interesting to see what this persons style/impact will be.
Excellent post!! Spot on assessment of one particular poster and their personal vendetta to keep Vivos and RDGL down. We longs have known this long time. There’s nothing “objective” about the posters intent. Once IDE submission is announced then approval, the positive news and market action will be such overwhelming force, the poster will move on,
Great postings Chereb!!! Keep it up! $RDGL
You got that right! BDD! IDE submission then IDE approval. Start clinical trials and successful phase 1. Going to be an epic 2024! $RDGL
Put the FUDster on ignore. It works wonders.
Correct. The guidance path Vivos has been on with FDA for the IDE application process and now with the recent BDD makes me more confident than ever Vivos will get IDE approval.
100%. Initial fun starts with IDE submission. Real fireworks happen with IDE approval and start of clinical trials. I expect they have a lot of other News also they’re holding back until IDE approval.
Unlikely given they’re probably finishing testing and then write up summary. Submission more probable for later February or early March. But who knows, they could surprise us.
Amazing how effective the ignore function is here. Better than a phone block on my ex lol.
Correct. As prestigious as Mayo is, it’s something not done on regular basis. Says a lot about MK and Vivos.
It shows how much confidence the Mayo clinic has in Dr Korenko and vivos and IDE approval so they can start clinical trials.
Yessir! Going to be an awesome 2024. IDE submission, then approval, then start clinical trials. $RDGL
The fact that BDD was granted so close to IDE submission bodes well for approval imo.
Agree. Put the FUDster on ignore.
Ignore his posts and replies and rest should take care of itself. Majority of posts were in response to his FUD.
Get Chereb and Cameron on board to ignore and that pretty much takes away ITS energy to continue FUD posting.
Agree. I put the 3letter FUDster on ignore. Take away the microphone and amazing how nice the silence is lol. Others should do the same. 3letter needs an audience to play to. Take away the audience and they dry up and disappear.
Agree. Having been in this ticker since early days of Katzaroff, the the risk factor, especially the last several months, and more so, as you mentioned with the BDD and FDA guidance path, has dropped considerably. I would say, being conservative, that IDE approval under the guidance path had been 75%+ before recent BDD. Now I’m betting 95% with BDD.
False. 4th quarter 10-Q is due April 1.
April 1 is the deadline. 4th quarter 2023 is included in the 2023 10-K filed by April 1.
I really don’t care what you think. So no reason to share what I know.
Expecting update, if not this coming short week, definitely the following week.
Restricted only increased by 500K shares. Small potatoes. Unrestricted still the same. MK very smart with controlling finances.
Broken record….
Why? It’s a personal vendetta he has against MK and the company. Long history of a fired disgruntled employee.
Nice try. Swing and a miss..again.
Every good CEO must be dynamic and fluid as they plot and traverse the course to lead the company to achieve its goals toward success. Korenko understands this and has done very well. That path to success is not always a straight line. Good leadership knows you often have to alter course or even take steps back to reroute the path to success. Only the fool of a captain directing his ship would continue the same trajectory when a torpedo is headed straight for it. I’ve no problems with Korenko having to alter course over the years to assure we arrive at the finish line.
That’s a lot of misguided hate and anger for someone who doesn’t hold shares.
I think only 10K needs to be filed for 2023 year, which includes the 4th qtr 10Q. Deadline is April 1.
Agree. Restricted only increased by 2.499M shares. Those haven’t entered the float and can’t be sold yet. Not a big deal by any stretch. MK is a very good steward of investor dollars and controlling expenses. One of the reasons he was made CEO.
Nothing wrong. People waiting for update on IDE submission.
Nice! Is the pps valuation for the buyout based on the AS or OS?
Agree. A good update and we should be at the $0.20-$0.30 range for correct valuation, pre submission news.
Yes, as mentioned, Cam’s wife is taking over his duties for Vivos.
And no mention of when update is coming.
Correct.
Real market awareness and change will come with the uplist to NASDAQ. Uplist likely after phase 1 trials.
Excellent post Kayak!!
Sorry for confusion if any. Person taking over X PR function not same person who left your group. No idea why they left group. Just left with no comments etc.
Agree Chereb. I’ve spoken to the person taking over his position several times who said Cam was a great asset and who loved Vivos and what they stood for. he was excited to see Vivos get IDE approval and approved for human use.
Just fyi that particular person no longer in other group.